ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 728

Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival

Bahar Artim-Esen1, Sevil Kamali1, Ahmet Gul1, Lale Ocal2 and Murat Inanc1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Anemia, Systemic lupus erythematosus (SLE) and thrombocytopenia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Hematologic involvement is common in patients with SLE. Thrombocytopenia and autoimmune hemolytic anemia (AIHA), prevalences of which have been reported as 10-40 % and 5-10 % respectively, have considerable impact on prognosis. Herein, we aimed to investigate the frequencies of these hemocytopenias, their clinical and serological associations and effect on disease outcome in a large single centre cohort of patients.

Methods:

We analysed our cohort of 852 patients who fulfilled at least 4 of the ACR criteria for SLE. The data presented was the cumulative clinical and serological manifestations throughout the follow-up period. Hemolytic anemia was defined as a drop in hemoglobin accompanied by increased reticulocyte count, high serum lactate dehydrogenase and reduced haptoglobin levels in the presence of a positive Coombs’ test. Thrombocytopenia was defined  as a platelet count of <100×109/mm3. Demographic characteristics, clinical features, autoantibody profiles, damage and mortality data retrieved from the database were compared between patients with and without each hematological abnormality. The Χ2 test, logistic regression and Kaplan-Meier survival analyses were used.  

Results:

There were 93 (10.9%) patients with AIHA and 215 (25.3%) with thrombocytopenia. Patients with AIHA was significantly younger  at diagnosis (27±13 vs 31±12, p<0.05) and  significantly had a shorter disease duration (95±84 vs 118±85 mo, p<0.05). AIHA and thrombocytopenia were both associated with neuropsychiatric (NP) involvement (p<0.05) and associated with each other (p<0.05) and leukopenia (p<0.05). Comparison of patients with AIHA or thrombocytopenia to the rest of the cohort displayed significant associations with antiphospholipid syndrome (APS), anticardiolipin (aCL) antibodies and lupus anticoagulant (LA). In patients with thrombocytopenia the relationship with APS features,  namely both  thrombosis and pregnancy morbidity, was stronger (p<0.001). Compared to the rest of the cohort, more patients in both groups had organ  damage and their mean SLICC damage score was significantly higher. Association to NP damage was discernible in both groups (p<0.05). In addition, damage in renal and cardiovascular domains and diabetes were more pronounced in patients with thrombocytopenia (p<0.001). Kaplan Meier survival analysis showed that patients with AIHA had significantly reduced survival rates at 10 (94 vs 77%) and 20 (88 vs 77%) years (p<0.001). In the thrombocytopenia group, despite the lack of significant differences, there was a tendency for lower survival rates.

Conclusion:

We demonstrated that both AIHA and thrombocytopenia were associated with aCL antibodies, coexisting APS and NP involvement and damage in our cohort. There was a strong link between AIHA and thrombocytopenia. Patients with AIHA had a younger age at disease onset with reduced survival. No significant reduction in survival rates was observed in patients with thrombocytopenia. However, besides NP involvement, thrombocytopenia delineated a subgroup of patients with a higher renal and cardiovascular damage which perceivably can affect prognosis. Overall, AIHA and thrombocytopenia may predict a poorer outcome in patients with SLE.


Disclosure: B. Artim-Esen, None; S. Kamali, None; A. Gul, None; L. Ocal, None; M. Inanc, None.

To cite this abstract in AMA style:

Artim-Esen B, Kamali S, Gul A, Ocal L, Inanc M. Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/autoimmune-hemolytic-anemia-and-thrombocytopenia-in-a-single-centre-cohort-of-patients-with-systemic-lupus-erythematosus-from-turkey-clinical-associations-and-effect-on-disease-damage-and-survival/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoimmune-hemolytic-anemia-and-thrombocytopenia-in-a-single-centre-cohort-of-patients-with-systemic-lupus-erythematosus-from-turkey-clinical-associations-and-effect-on-disease-damage-and-survival/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology